Skip to main content

MTIP using new fund to invest in innovative companies

| News

MTIP using new fund to invest in innovative companies


The Basel-based firm MTIP AG specializes in investments in HealthTech companies. A total of 130 million euros has already been raised for a new fund. This capital will be invested in companies operating in the fields of digital health and connected medical devices.

Private equity firm MTIP invests in digital health, combining innovation and medical practice (img: MTIP)

MTIP AG has now raised a total of 130 million euros for its fund MTIP FUND II, SCSp. The first closing has now been completed, details of which can be found in a press release issued by MTIP. The target volume amounts to 200 million euros, with the fund serving to facilitate investments in companies operating in areas such as digital health and connected medical devices. In addition to being “primarily” based in Europe, it is also essential that the companies offer “differentiated” solutions. According to Christoph Kausch, Managing Partner at MTIP, the total of 130 million euros means that MTIP has “overachieved our expectations”. While he also describes the first closing as “an enormously important milestone in our company history”.

The total of 130 million euros raised so far has been sourced from various investors. Moreover, MTIP works with the European Investment Fund (EIF) as an anchor investor. “MTIP’s fund strategy fits with EIF’s ambition of financing the vital growth segment of the European Venture Capital ecosystem, which is largely underfunded and overly dependent on non-European investors for larger investments”, comments Alain Godard, Chief Executive of EIF, in the press release.

The fund has already invested in three companies. The first, Oviva, is active in the area of nutrition consulting, while the second, Trialbee, focuses on patient recruitment for clinical trials, and the third, Koa Health, develops digital treatments for mental illnesses. Kausch believes that these and further investments will create “strong momentum towards the final close”.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.